WO1999023111A1 - Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma - Google Patents

Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma Download PDF

Info

Publication number
WO1999023111A1
WO1999023111A1 PCT/CA1998/001008 CA9801008W WO9923111A1 WO 1999023111 A1 WO1999023111 A1 WO 1999023111A1 CA 9801008 W CA9801008 W CA 9801008W WO 9923111 A1 WO9923111 A1 WO 9923111A1
Authority
WO
WIPO (PCT)
Prior art keywords
solution
thrombin
proteins
precipitate
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA1998/001008
Other languages
English (en)
French (fr)
Inventor
Trung Bui-Khac
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Haemacure Corp Canada
Original Assignee
Haemacure Corp Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ504246A priority Critical patent/NZ504246A/xx
Priority to DE69831684T priority patent/DE69831684T2/de
Priority to PL98340300A priority patent/PL194589B1/pl
Priority to AU97316/98A priority patent/AU759145B2/en
Priority to IL135812A priority patent/IL135812A/en
Priority to CA002307380A priority patent/CA2307380A1/en
Priority to JP2000518981A priority patent/JP4278861B2/ja
Priority to EP98951133A priority patent/EP1027371B1/en
Priority to AT98951133T priority patent/ATE305011T1/de
Application filed by Haemacure Corp Canada filed Critical Haemacure Corp Canada
Publication of WO1999023111A1 publication Critical patent/WO1999023111A1/en
Priority to NO20002293A priority patent/NO323299B1/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/022—Filtration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
    • A61L24/10—Polypeptides; Proteins
    • A61L24/106—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/908—Mechanical repair performed/surgical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/92—Detection of biochemical

Definitions

  • Pasteurization of albumin and IgGs appeared at the beginning of the 50s. This technique, however, was directed to inactivation of hepatitis virus (hepatitis B and non A-non B). Curran et al. (1984) raised the issue of viral transmission of HIV type by transfusion or the use of other blood derivatives, particularly coagulation factors. Since then, methods of viral inactivation focused on HIV. No HIV transmission was signaled from the use of albumin or IgGs, this lack of viral transmission being assigned to the step of pasteurization (Mitra et al. (1986)). Coagulation factors such as factor VIII and IX are widely used by hemophilic patients. Heimburger et al.
  • Studies conducted on 29 patients having received these heat-treated products have shown that there was no seroconversion of HIV of HB and that there was a significative reduction of the incidence of transmission of NANBH.
  • Other methods of viral inactivation have been developed using a light sources (UV, gamma rays, and laser) to irradiate the infectious agents in plasma.
  • step b) is preferably made in 1% Tris and 1.6% sodium citrate pH 6 to 7.3 or pH 9.5 to 10.5 to bring the protein concentration to about 20-22 mg/mL before adding L-Histidine.
  • the cation exchange medium is said non-compressible composite medium of sulfoalkyl-activated dextran and silica particles.
  • the precipitate obtained rich in fibrinogen, factor XIII and fibronectin, is soiubilized with a buffer containing 1% Tris and 1.6% sodium citrate pH: 6.0 ⁇ 0.1 (pH 7.3 also works).
  • the precipitate is soiubilized at room temperature, under agitation.
  • the buffer described above is added as needed to get a protein concentration of about 20 - 22 mg/ml.
  • L-Histidine is added at the rate of 0.2 - 0.3 g per gram of protein.
  • the protein solution is then centrifuged at 10,000 rpm for 20 minutes at about 4° C (Beckman J2-MI, rotor JA-10 type). A lipid layer floating at the surface of the protein solution is removed.
  • the protein solution is gently transferred into a beaker and filtered through a 0.2 micron capsule filter (Gelman SuporCap, product N 2 12991 or 12992).
  • a quantity of 50 mM amino-6 hexanoic acid is added to the filtrate under agitation and the mixture is incubated at 35° C ⁇ 2° C for about one hour and then cooled down to 0° C ⁇ 2° C.
  • a quantity of sodium or potassium phosphate monobasic U.S.P N 2 5,290,91 ⁇ issued to Haemacure Biotech Inc.
  • sodium or potassium acetate U.S.P. N 2 5,395,923 issued to Haemacure Biotech Inc.
  • Centrifugation The mixture is filtered or centrifuged at 4,200 rmp (Beckman J6-MC, rotor 4.2 type) for 20 minutes at 4° C. The solvent, the detergent and the contaminating proteins are eliminated by centrifugation. The precipitate is recovered and transferred into a beaker.
  • the protein solution is filled into 10 ml vials at the rate of 60 ⁇ 5 mg of clotable fibrinogen per vial. Lyophilization:
  • the diafiltered thrombin solution is then filtered over a hollow-fiber membrane such as a Planova BMM microporous membrane (Bemberg microporous membrane BMM Development, Asahi Chemical Industries, Tokyo, Japan) comprising a cuprammonium regenerated cellulose fiber having a pore size of about 15 nm.
  • a Planova BMM microporous membrane Bemberg microporous membrane BMM Development, Asahi Chemical Industries, Tokyo, Japan
  • This technique substantially allows the remove non-lipid-enveloped viruses which cannot be inactivated by SD treatment of the process.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
PCT/CA1998/001008 1997-10-30 1998-10-29 Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma Ceased WO1999023111A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP98951133A EP1027371B1 (en) 1997-10-30 1998-10-29 Process for the production of highly viral safe thrombin for forming fibrin glue from a pool of human plasma
DE69831684T DE69831684T2 (de) 1997-10-30 1998-10-29 Verfahren zur Herstellung von hochvirusfreiem Thrombin zur Bereitung von Fibrinkleber aus menschlichem Plasma-Pool
PL98340300A PL194589B1 (pl) 1997-10-30 1998-10-29 Sposób wytwarzania trombiny
AU97316/98A AU759145B2 (en) 1997-10-30 1998-10-29 Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma
IL135812A IL135812A (en) 1997-10-30 1998-10-29 Process for the production of thrombin from plasma
NZ504246A NZ504246A (en) 1997-10-30 1998-10-29 Production of virion-free thrombin recovered from whole plasma from which fibrinogen, Factor VIII and fibronectin have been precipitated
JP2000518981A JP4278861B2 (ja) 1997-10-30 1998-10-29 ウイルス汚染に対する安全性の高いフィブリンのり形成用成分をヒト血漿プールから製造する方法
CA002307380A CA2307380A1 (en) 1997-10-30 1998-10-29 Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma
AT98951133T ATE305011T1 (de) 1997-10-30 1998-10-29 Verfahren zur herstellung von virusfreien thrombin zur bereitung von fibrinkleber aus menschlichem plasma-pool
NO20002293A NO323299B1 (no) 1997-10-30 2000-04-28 Fremgangsmate til fremstilling trombin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/960,660 US5981254A (en) 1997-10-30 1997-10-30 Process for producing thrombin from plasma
US08/960,660 1997-10-30

Publications (1)

Publication Number Publication Date
WO1999023111A1 true WO1999023111A1 (en) 1999-05-14

Family

ID=25503448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1998/001008 Ceased WO1999023111A1 (en) 1997-10-30 1998-10-29 Process for the production of highly viral safe components for forming fibrin glue from a pool of human plasma

Country Status (16)

Country Link
US (1) US5981254A (https=)
EP (1) EP1027371B1 (https=)
JP (1) JP4278861B2 (https=)
AT (1) ATE305011T1 (https=)
AU (1) AU759145B2 (https=)
CA (1) CA2307380A1 (https=)
DE (1) DE69831684T2 (https=)
DK (1) DK1027371T3 (https=)
ES (1) ES2249843T3 (https=)
IL (1) IL135812A (https=)
IN (1) IN185759B (https=)
NO (1) NO323299B1 (https=)
NZ (1) NZ504246A (https=)
PL (1) PL194589B1 (https=)
RU (1) RU2236237C2 (https=)
WO (1) WO1999023111A1 (https=)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001048016A1 (en) * 1999-12-23 2001-07-05 Csl Limited Separation of fibrinogen from plasma proteases
JP2002114799A (ja) * 2000-08-01 2002-04-16 Nihon Pharmaceutical Co Ltd ウイルス除去方法
EP1348445A1 (de) * 2002-03-15 2003-10-01 Aventis Behring GmbH Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
EP1457497A1 (en) * 2003-03-06 2004-09-15 Probitas Pharma, S.A. Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process
EP1250929A4 (en) * 1999-12-20 2004-12-29 Mitsubishi Pharma Corp BY POROUS MEMBRANE-TREATED, VIRUS-FREE PLASMA PROTEIN COMPOUND AND ITS MANUFACTURING PROCESS
AU779126B2 (en) * 1999-12-23 2005-01-06 Csl Limited Separation of fibrinogen from plasma proteases
EP1649867A1 (en) 2004-10-22 2006-04-26 Grifols, S.A. Stable thrombin composition
US7816495B2 (en) 2002-07-10 2010-10-19 Nhs Blood And Transplant Processes for the preparation of fibrinogen
US8598319B2 (en) 2005-06-29 2013-12-03 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins
EP2329019B1 (en) * 2008-08-08 2014-03-12 Cambridge Enterprise Limited Isolation of nucleic acid
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
WO2023020914A1 (en) 2021-08-18 2023-02-23 Biotest Ag Dry heat treatment of plasma-derived factor viii

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT407484B (de) * 1997-11-12 2001-03-26 Bio Prod & Bio Eng Ag Arzneimittel zur förderung der wundheilung
US7411006B2 (en) 2000-10-23 2008-08-12 Shanbrom Technologies, Llc Enhanced production of blood clotting factors and fibrin fabric
US7365173B2 (en) * 2002-02-04 2008-04-29 American National Red Cross Method for the production of pure virally inactivated butyrylcholinesterase
US20060275829A1 (en) * 2002-04-15 2006-12-07 Hammond David J Combinatorial library for proteomic investigations
US20070015230A1 (en) * 2002-04-15 2007-01-18 Hammond David J Identification and characterization of analytes from whole blood
US20060275753A1 (en) * 2002-04-15 2006-12-07 Hammond David J Recovery of analytes using combinatorial libraries
AU2003231731A1 (en) * 2002-04-15 2003-11-03 American National Red Cross Method for detecting ligands and targets in a mixture
DK1528930T3 (da) * 2002-07-23 2009-08-03 Bio & Bio Licensing Sa Thrombindannelsesdygtige og thrombinholdige farmaceutiske præparater af virksomt stof samt lægemidler
EP1711513B1 (en) * 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration of factor vii solutions to remove virus
WO2006009989A1 (en) * 2004-06-22 2006-01-26 Zymogenetics, Inc. Thrombin compositions
DE102004044429B4 (de) * 2004-09-14 2009-04-30 Biotest Ag Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor
US20060270015A1 (en) * 2005-05-26 2006-11-30 Dan Pawlak Thrombin purification
US20120195953A1 (en) * 2007-09-19 2012-08-02 Kieu Hoang Fibrin sealant (FIBRINGLURAAS) consisting of a kit of lyophilized high concentrate fribinogen intentionally enriched and preserved with fibronolysis inhibitor A1AT
RU2369410C1 (ru) * 2008-05-06 2009-10-10 Александр Николаевич Данилин Способ очистки биологической жидкости организма (крови) от вирусной инфекции путем сорбции на магнитоуправляемых наночастицах и устройство для его осуществления
PT2900247T (pt) * 2012-09-26 2018-03-28 Bone Therapeutics Sa Composições contendo plasma tratado com dissolventes/detergentes e ácido hialurónico para serem utilizadas no tratamento de distúrbios músculo-esqueléticos
RU2583931C2 (ru) * 2014-06-11 2016-05-10 Федеральное государственное бюджетное учреждение Гематологический научный центр Министерства здравоохранения РФ Способ получения концентрата тромбина
US9932388B2 (en) 2014-11-13 2018-04-03 Hemarus Therapeutics Limited Chromatographic process for producing high purity fibrinogen and thrombin
JP6666757B2 (ja) * 2016-03-10 2020-03-18 日本メジフィジックス株式会社 ポリオキシエチレン系非イオン界面活性剤の定量方法及び放射性医薬品製剤の製造方法
JP2021513913A (ja) * 2018-02-19 2021-06-03 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 修正フィルタ膜及び方法
WO2020229521A1 (en) 2019-05-14 2020-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for inhibiting or reducing bacterial biofilms on a surface
CN113754757B (zh) * 2021-07-01 2024-06-14 华兰生物工程股份有限公司 一种人纤维蛋白原的制备方法
KR20230121373A (ko) * 2022-02-11 2023-08-18 주식회사 녹십자 인자 xiii의 정제방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290918A (en) * 1993-02-23 1994-03-01 Haemacure Biotech Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
WO1996009376A1 (en) * 1994-09-21 1996-03-28 Haemacure Biotech Inc. Therapeutic grade thrombin production and products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843126C3 (de) * 1988-12-22 1994-10-06 Octapharma Ag Verfahren zur Herstellung eines hochreinen Thrombinkonzentrates
RU2030183C1 (ru) * 1989-07-13 1995-03-10 Наталья Юрьевна Шатковская Состав для соединения биопластических материалов в отохирургии
RU2049470C1 (ru) * 1990-04-20 1995-12-10 Новокузнецкий институт усовершенствования врачей Способ получения альфа-макроглобулина
FR2679251B1 (fr) * 1991-07-18 1993-11-12 Nord Assoc Essor Transfusion San Procede de preparation d'un concentre de thrombine humaine destine a un usage therapeutique.
RU2062103C1 (ru) * 1994-09-29 1996-06-20 Московская медицинская академия им.И.М.Сеченова Способ получения концентрата фибриногена

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5290918A (en) * 1993-02-23 1994-03-01 Haemacure Biotech Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by acidic precipitation
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
WO1996009376A1 (en) * 1994-09-21 1996-03-28 Haemacure Biotech Inc. Therapeutic grade thrombin production and products

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1250929A4 (en) * 1999-12-20 2004-12-29 Mitsubishi Pharma Corp BY POROUS MEMBRANE-TREATED, VIRUS-FREE PLASMA PROTEIN COMPOUND AND ITS MANUFACTURING PROCESS
JP2003518513A (ja) * 1999-12-23 2003-06-10 シーエスエル、リミテッド 血漿プロテアーゼからのフィブリノゲンの分離
AU779126B2 (en) * 1999-12-23 2005-01-06 Csl Limited Separation of fibrinogen from plasma proteases
US6960463B2 (en) 1999-12-23 2005-11-01 Csl Limited Separation of fibrinogen from plasma proteases
WO2001048016A1 (en) * 1999-12-23 2001-07-05 Csl Limited Separation of fibrinogen from plasma proteases
JP2002114799A (ja) * 2000-08-01 2002-04-16 Nihon Pharmaceutical Co Ltd ウイルス除去方法
AU2003200981B2 (en) * 2002-03-15 2008-11-20 Csl Behring Gmbh Method for separating off viruses from a protein solution by means of nanofiltration
EP1348445A1 (de) * 2002-03-15 2003-10-01 Aventis Behring GmbH Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
US7919592B2 (en) 2002-03-15 2011-04-05 Zlb Behring Gmbh Method for separating off viruses from a protein solution by means of nanofiltration
KR100998158B1 (ko) 2002-03-15 2010-12-06 체에스엘 베링 게엠베하 나노여과에 의해서 단백질 용액으로부터 바이러스를 분리제거하는 방법
US7816495B2 (en) 2002-07-10 2010-10-19 Nhs Blood And Transplant Processes for the preparation of fibrinogen
AU2004200745B8 (en) * 2003-03-06 2009-01-08 Grifols, S.A. Process for Removing Viruses in Fibrinogen Solutions and Fibrinogen Obtained by Said Process
US7442308B2 (en) 2003-03-06 2008-10-28 Grifols, S.A. Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process
AU2004200745B2 (en) * 2003-03-06 2008-07-03 Grifols, S.A. Process for Removing Viruses in Fibrinogen Solutions and Fibrinogen Obtained by Said Process
EP1457497A1 (en) * 2003-03-06 2004-09-15 Probitas Pharma, S.A. Process for removing viruses in fibrinogen solutions and fibrinogen obtained by said process
EP1649867A1 (en) 2004-10-22 2006-04-26 Grifols, S.A. Stable thrombin composition
US9376674B2 (en) 2004-10-22 2016-06-28 Grifols, S.A. Process to prepare a stable thrombin composition
EP2772499A1 (fr) 2005-06-29 2014-09-03 Laboratoire Français du Fractionnement et des Biotechnologies Separation de proteines plasmatiques
US9320779B2 (en) 2005-06-29 2016-04-26 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins
US9339530B2 (en) 2005-06-29 2016-05-17 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins
US8598319B2 (en) 2005-06-29 2013-12-03 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Process for separating proteins fibrinogen, factor XIII and biological glue from a solubilized plasma fraction and for preparing lyophilised concentrates of said proteins
EP2329019B1 (en) * 2008-08-08 2014-03-12 Cambridge Enterprise Limited Isolation of nucleic acid
US9422543B2 (en) 2008-08-08 2016-08-23 Cambridge Enterprise Limited Isolation of nucleic acid
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
WO2023020914A1 (en) 2021-08-18 2023-02-23 Biotest Ag Dry heat treatment of plasma-derived factor viii

Also Published As

Publication number Publication date
DE69831684T2 (de) 2006-06-22
IL135812A0 (en) 2001-05-20
NO20002293L (no) 2000-06-30
PL194589B1 (pl) 2007-06-29
EP1027371B1 (en) 2005-09-21
PL340300A1 (en) 2001-01-29
IL135812A (en) 2007-09-20
CA2307380A1 (en) 1999-05-14
AU759145B2 (en) 2003-04-03
JP2001521941A (ja) 2001-11-13
NZ504246A (en) 2002-09-27
NO20002293D0 (no) 2000-04-28
NO323299B1 (no) 2007-03-05
US5981254A (en) 1999-11-09
IN185759B (https=) 2001-04-21
ES2249843T3 (es) 2006-04-01
EP1027371A1 (en) 2000-08-16
DE69831684D1 (de) 2006-02-02
JP4278861B2 (ja) 2009-06-17
AU9731698A (en) 1999-05-24
ATE305011T1 (de) 2005-10-15
RU2236237C2 (ru) 2004-09-20
DK1027371T3 (da) 2006-01-09

Similar Documents

Publication Publication Date Title
US5981254A (en) Process for producing thrombin from plasma
US5099003A (en) Method of preparing a sterile plasma-protein solution containing fibrinogen and factor xiii
CA1329542C (en) Plasma and recombinant protein formulations in low ionic strength media
US5834420A (en) Fibrinogen concentrate obtained from blood plasma, process and plant for its preparation
JP3628703B2 (ja) 治療グレードトロンビン産物及び製品
JP4324102B2 (ja) フィブリノーゲンの調製方法
JP2013047273A (ja) 可溶化血漿フラクションから蛋白質フィブリノーゲン、第ｘｉｉｉ因子および生物学的グルーを分離し、そして該蛋白質の凍結乾燥濃縮物を調製するための方法
US4379085A (en) Heat stabilization of plasma proteins
JP4925822B2 (ja) ウイルス不活性化熱処理へ供するための血漿タンパク質の寒冷沈降物を安定化する方法
FI81363C (fi) Foerfarande foer pastoerisering av preparat av blodkoaguleringsfaktorerna ii, vii, ix och x.
IE842180L (en) Pasteurization of human plasma
WO1998030230A1 (en) Protein-containing compositions and process for producing the same
MX2007014571A (es) Purificacion de trombina.
RU2045902C1 (ru) Состав для стабилизации плазмы крови в ходе пастеризации и способ пастеризации плазмы крови
AU756017B2 (en) The process of preparing immunoglobulin for intravenous injection by viruses double-sterilized without adding any protectant
RU2253475C1 (ru) Способ получения препарата фактора viii
JPS59167519A (ja) 不活化トロンビンゲルにより血漿タンパク質混合液からフイブリノ−ゲンを除去する方法
JPWO1998030230A1 (ja) 蛋白質含有組成物及びその製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2307380

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2307380

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 504246

Country of ref document: NZ

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 97316/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998951133

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998951133

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 97316/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1998951133

Country of ref document: EP